16 results about "Effector functions" patented technology

The invention relates to lymphocytes which are genetically engineered to overexpress one or more maintenance factor(s), wherein, as compared to a corresponding lymphocyte which is not engineered to overexpress said one or more maintenance factor(s), the lymphocytes exhibit enhanced stem-like or memory phenotype and a comparable or greater level of one or more effector functions in response to immune stimulation and a comparable or greater level of proliferation. The invention also relates to use of said lymphocytes in therapy, to methods for identifying said lymphocytes, and to methods for producing said lymphocytes.

Provided are proteins and molecules comprising a variant Fc region or a variant CH2 domain with significantly reduced binding to FcγR family receptors and reduced effector functions. Methods of producing and using such proteins and molecules are also provided.

This article describes antibodies or antigen-binding fragments that specifically bind to GPRC5D. Additionally, it includes monovalent antibodies or antigen-binding fragments that specifically bind to GPRC5D. The Fc regions of these antibodies contain K248E and T437R mutations (referred to as “RE mutations”) according to the EU numbering system. The described antibodies, when expressed in host cells lacking fucosylation capacity, exhibit enhanced antibody-dependent cytotoxicity (ADCC) and enhanced complement-dependent cytotoxicity (CDC).

The present disclosure provides super-repressors capable of inhibiting the transcription of NR4A1, NR4A2, and NR4A3 target genes. The super-repressors can be used to enhance the effector functions of immune cells, e.g., for adoptive cell therapy. Methods of treating disorders using the modified immune cells are also provided.

This invention relates to IgG1 Fc variants that do not elicit antibody effector functions such as CDC, ADCP, and ADCC. In particular, this invention relates to IgG1 Fc variant peptides comprising mutants L234A, L235A, A327G, P329A, A330S, and P331S according to EU designations, molecules comprising such IgG1 Fc variant peptides, and the use of such molecules to reduce antibody effector functions.

The invention refers to anti-oxMIF antibodies with improved properties such as reduced aggregation potential and reduced hydrophobicity due to selected amino acid substitutions in the light and heavy chain variable domains and optionally increased effector functions due to further substitutions in the heavy chain constant regions, and their use in the treatment of oxMIF-related conditions.

The present specification discloses modified anti-PD-Ll antibodies that eliminate Fc- associated effector functions and enhance clearance while maintaining therapeutic efficacy on neurodegenerative disease alterations. The present specification also discloses nucleic acid sequences and expression constructs encoding such modified anti-PD-Ll antibodies, and methods of making such modified anti-PD-Ll antibodies. In addition, the present specification discloses methods of treatment and uses employing administration regimens of the disclosed anti-PD-Ll antibodies that ensure that the antibodies are only present for a specific period of time and then are sufficiently cleared from the body to ensure maintenance of therapeutic efficacy.

The invention belongs to the field of immunology, and particularly relates to a method for constructing an animal model and application thereof. The method comprises the following steps: firstly, providing a method for constructing a mouse model, namely constructing four transgenic mice by using artificial chromosomes, two different DNA recombinase and three different reporter genes, and mating to obtain the transgenic mice carrying the three different reporter genes at the same time, the mouse can be used for tracking Th1 cell differentiation and central memory T cell development in an animal body. The invention also provides a method for evaluating the immune efficacy of the vaccine, which comprises the following steps: immunizing a mouse according to an immune procedure and a dose capable of causing immune response, extracting lymphocytes of the mouse, performing flow cytometry staining, and observing a result. Through a constructed mouse model, it is found that differentiated Th1 type effector cells capable of stably expressing T-bet can be developed into CCR7 + CD4 + TCM cells, and analysis of functions and development differentiation of the cells can provide a new thought for development of cellular immune vaccines with higher effector functions and long protection periods.

The invention provides antibody heavy chain constant regions with a hinge region modified to reduce binding to Fcγ receptors. The modification occurs within positions 233-236 by replacement of natural residues by glycine(s) and / or deletion(s). Such modifications can reduce binding of an antibody bearing such a constant region to Fcγ receptors to background levels. The constant regions can be incorporated into any format of antibody or Fc fusion protein. Such antibodies or fusion proteins can be used in methods of treatment, particularly those in which the mechanisms of action of the antibody or Fc fusion protein is not primarily or at all dependent on effector functions, as is the case when an antibody inhibits a receptor-ligand interaction or agonizes a receptor.

Provided herein are methods for: (1) rapidly depleting circulating B cells and remodeling one or more B cell compartments, (2) treating B cell-related autoimmune diseases, and (3) B cell malignancies, using B cell depleting antibodies that are directed to CD19 or CD20 and one or more target antigens. Further provided herein is a CD19 / CD20 bispecific antibody with dual Fc domains that mediate enhanced effector functions and B cell depletion. HB2198 demonstrated enhanced binding to Fcγ receptors, potent effector functions, and efficient depletion of B cells in vitro and in vivo.

Feline, canine, and equine antibody variants and uses thereof, as well as compositions and methods for improving therapeutic monoclonal antibodies by modulating immune effector functions and antibody variants using those methods and compositions.

The invention relates to lymphocytes which are genetically engineered to overexpress one or more maintenance factor(s), wherein, as compared to a corresponding lymphocyte which is not engineered to overexpress said one or more maintenance factor(s), the lymphocytes exhibit enhanced stem-like or memory phenotype and a comparable or greater level of one or more effector functions in response to immune stimulation and a comparable or greater level of proliferation. The invention also relates to use of said lymphocytes in therapy, to methods for identifying said lymphocytes, and to methods for producing said lymphocytes.

Provided herein are combinations of first and second antibodies having modified Fc effector functions resulting from amino acid substitutions in the Fc region, the amino acid substitutions allow for co-dependent activation of effector functions such as CDC and / or ADCC. Also provided are combinations of first and second antibodies having agonistic activity or enhanced agonistic activity resulting from amino acid substitutions in the Fc region where the agonistic activity is co-dependent of both a first and second antibodies.

The present disclosure provides compositions and methods for inhibiting T cell senescence and improving T cell immunotherapies. In particular, inhibitors of group IV A phospholipase A2 are disclosed as useful in modulating the lipid metabolism of cells, in particular effector T cells, such that T reg- and tumor cell-induced cell senescence is abrogated. These methods may be employed with particular utility in adoptive T cell therapies and / or enhanced T cell effector functions in vivo, including those performed in combination with checkpoint blockade therapies.

The invention discloses an immune cell for improving an anti-tumor curative effect through gene regulation, a preparation method and application. After the MSN is knocked out, the enhancement of an IL-2 / IL-15 signal channel of the immune cell is promoted, and the immune cell is further enabled to be in an environment containing IL-2 and / or IL-15, so that the enhancement of one or more effector functions of the immune cell can be promoted; the present invention relates to immune cells comprising increased proliferation in a host following adoptive metastasis, increased infiltration to a tumor, sustained presence of immune cells in a subject, and / or increased resistance to immune cell depletion. Particularly, the multiplication capacity in a host after adoptive metastasis is promoted, so that the tumor cell killing effect of the cells is remarkably improved.

This specification provides polymers that conditionally induce cellular effector functions (e.g., biological or therapeutic activity) based on the presence of disease signature ligands, compositions containing the same, and methods of using the same. In some embodiments, the cellular effector function includes therapeutic activity. In some embodiments, the cellular effector function includes disease activity. In some embodiments of any of the above embodiments, the cellular effector function is biological activity. In some embodiments, the cellular effector function is therapeutic activity. In some embodiments, the cellular effector function is disease activity.